Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 94 of 94 results for dexamethasone

  1. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

    In development [GID-TA10726] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

    NICE guideline
    Last updated
    15 December 2021
    View recommendations

    Sections for NG131

  3. New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE

    Around 5,700 cases of multiple myeloma are diagnosed each year in the UK

    News
    Published
    24 November 2020

  4. Triple therapy recommended by NICE for patients with multiple myeloma

    The therapy has been recommended after a confidential discount was agreed between NHS England and the drug manufacturer Amgen.

    News
    Published
    22 March 2021